pre-IPO PHARMA

COMPANY OVERVIEW

Ervaxx is pioneering the use of Dark Antigens™ to deliver targeted off-the-shelf cancer vaccines and other immunotherapies for treating and preventing cancer.


LOCATION

  • London, , UK
  • Oxford, , uk

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://ervaxx.com


    CAREER WEBSITE

    https://ervaxx.com/careers


    SOCIAL MEDIA


    INVESTORS

    sv-health-investors


    PRESS RELEASES


    Jan 24, 2020

    Ervaxx and Cardiff University Enter Collaboration to Develop Novel T-cell and T-cell Receptor-based Immunotherapeutics Targeting Dark Antigens™


    Nov 6, 2019

    Ervaxx Launches to Pioneer the Use of Dark Antigens™ for the Development of Off-the-Shelf Cancer Vaccines and T-cell Receptor-based Immunotherapies


    For More Press Releases


    Google Analytics Alternative